Next |
home / stock / prds / prds message board
Subject | By | Source | When |
---|---|---|---|
$PRDS fails phase-2 COVID trialterminates program: | DewDiligence | investorshub | 04/03/2023 2:21:44 PM |
PRDS 4Q22 results: | DewDiligence | investorshub | 03/14/2023 8:07:28 PM |
$PBI-451 is now known as Pomotrelvir: | DewDiligence | investorshub | 02/14/2023 7:52:33 PM |
$PRDS 3Q22 results9/30/22 cash=$209M: | DewDiligence | investorshub | 11/07/2022 11:14:58 PM |
The daily dose of PBI-0451 in the phase-2 | DewDiligence | investorshub | 09/14/2022 8:57:46 PM |
PRDS starts phase-2 trial of PBI-0451-vs-placebo in non-hospitalized, | DewDiligence | investorshub | 09/13/2022 2:00:35 PM |
$PRDS 3/31/22 cash=$247.9M, a reduction of $20.8M relative | DewDiligence | investorshub | 05/10/2022 9:53:10 PM |
Shionogi out as a serious COVID competitor: #msg-168536263. | DewDiligence | investorshub | 04/13/2022 3:49:57 PM |
$PRDS 4Q21 financials12/31/21 cash=$269M: | DewDiligence | investorshub | 03/29/2022 8:22:15 PM |
New corporate slide set: | DewDiligence | investorshub | 03/09/2022 4:21:33 PM |
$PRDS changes CEO (to stop the bleeding): | DewDiligence | investorshub | 03/02/2022 9:33:13 PM |
$PRDS is leaning toward a 1400mg daily dose | DewDiligence | investorshub | 02/16/2022 4:01:28 PM |
$PRDS slides for PBI-0451(nonclinical and phase-1a in healthy volunteers) from | DewDiligence | investorshub | 02/14/2022 4:06:11 PM |
FDA clears IND for PBI-0451, enabling the start | DewDiligence | investorshub | 02/03/2022 2:47:18 PM |
PRDS phase-1a is investigating ritonavir boosting: | DewDiligence | investorshub | 01/24/2022 8:21:38 PM |
$PRDS S-1 filing for registration of insider shares: | DewDiligence | investorshub | 01/23/2022 8:40:12 PM |
Corporate slide set#24-28 of most interest: | DewDiligence | investorshub | 01/07/2022 5:02:05 PM |
$PRDS > SEC filing Form 4 > Foresite | crudeoil24 | investorshub | 12/30/2021 10:08:54 PM |
Looks good. Covid play | pauljack13 | investorshub | 12/30/2021 8:17:18 PM |
17.17 up 26% | crudeoil24 | investorshub | 12/30/2021 5:36:39 PM |
News, Short Squeeze, Breakout and More Instantly...
Pardes Biosciences Inc. Company Name:
PRDS Stock Symbol:
NASDAQ Market:
CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully comp...
As previously announced, on July 16, 2023, MediPacific Sub, Inc. (“Purchaser”) and MediPacific, Inc. (“Parent”), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the “Merger Agreement”) with Pardes Biosciences, Inc. ...
NEW YORK, NY / ACCESSWIRE / August 9, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chase Corporation (NY...